EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase II)VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Effects of Siltuximab Versus Corticosteroids in Preventing COVID −19 Pneumonia Disease Progression: Multicentre, Open‐Label, Randomized Clinical Trial

Lorna Leal, María Del Puerto Bernoy González, Clara Castán, Fernanda Meira iD, Gerard Dueñas iD, Judit Pich, Marta Hernández-Meneses iD, Verónica Rico, Nicole García-Pouton, Daiana Agüero, Elisa de Lazzari iD, Adrià Tomé und 14 weitere

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70491 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Lorna Leal und 25 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hospital Clínic Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Antibodies, Monoclonal, COVID-19, COVID-19 Drug Treatment. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2020, COVID‐19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open‐label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID‐19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50–72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids ( p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission (2.7; 95% CI, 1.11–6.62), lower risk of requiring mechanical ventilation (0.43; 95% CI, 0.20–0.93) and shorter hospitalization duration ( p = 0.008). Mortality was similar between arms ( p = 0.675). Twenty‐eight patients receiving siltuximab required rescue therapy while only 5 receiving corticosteroids ( p < 0.001). Furthermore, patients receiving corticosteroids had a 53% lower risk of confirmed bacterial or fungal invasive infections (RR 0.47; 95% CI, 0.23–0.95; p = 0.0096). Our results show that initial treatment with corticosteroids was more effective than siltuximab in preventing disease progression, reducing intensive care unit admission, mechanical ventilation, with shorter hospital stays, and fewer infection in COVID‐19 pneumonia. Despite numerous challenges, these findings provide valuable insights into optimizing therapeutic strategies, supporting corticosteroids as a preferred treatment over siltuximab in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Cortex HormonesAntibodies, MonoclonalCOVID-19COVID-19 Drug TreatmentAgedFemaleHumansMaleMiddle AgedDexamethasoneDisease ProgressionIntensive Care UnitsMethylprednisoloneRespiration, ArtificialSARS-CoV-2Treatment Outcome

Stichwörter der Autor:innen

ICUIL‐6 antagonistscovid‐19dexamethasonesiltuximab

Substanzen

Adrenal Cortex HormonesAntibodies, MonoclonalDexamethasoneMethylprednisolonesiltuximab

Autor:innen und Institutionen

  • Infectious Diseases Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
  • Clinical Trials Unit (CTU), Hospital Clínic Barcelona, Barcelona, Spain.
  • Department of Internal Medicine, Hospital Clínic Barcelona, Barcelona, Spain.
  • Institute for Global Health (ISGlobal), Barcelona, Spain.

ORCID-Profile: Fernanda Meira, Gerard Dueñas, Marta Hernández-Meneses, Elisa de Lazzari, Pedro Castro

Zitieren

APA

Leal, L., Del Puerto Bernoy González, M., Castán, C., Meira, F., Dueñas, G., Pich, J., Hernández-Meneses, M., Rico, V., García-Pouton, N., Agüero, D., de Lazzari, E., Tomé, A., Herrera, S., Muñóz, J., Almuedo, A., Prieto-González, S., Castro, P., Marcos, M. A., Tuset, M., …, & SILCOR study group (2026). Effects of Siltuximab Versus Corticosteroids in Preventing COVID −19 Pneumonia Disease Progression: Multicentre, Open‐Label, Randomized Clinical Trial. Clinical and Translational Science. https://doi.org/10.1111/cts.70491

Vancouver

Leal L, Del Puerto Bernoy González M, Castán C, Meira F, Dueñas G, Pich J, et al. Effects of Siltuximab Versus Corticosteroids in Preventing COVID −19 Pneumonia Disease Progression: Multicentre, Open‐Label, Randomized Clinical Trial. Clinical and Translational Science. 2026. doi:10.1111/cts.70491

BibTeX
@article{Leal2026,
  author = {Leal, Lorna and Del Puerto Bernoy González, María and Castán, Clara and Meira, Fernanda and Dueñas, Gerard and Pich, Judit and Hernández-Meneses, Marta and Rico, Verónica and García-Pouton, Nicole and Agüero, Daiana and de Lazzari, Elisa and Tomé, Adrià and Herrera, Sabina and Muñóz, José and Almuedo, Alex and Prieto-González, Sergio and Castro, Pedro and Marcos, Maria Angeles and Tuset, Montse and Paredes, Roger and Carbonell, Cristina and Dalmau, David and Martínez, José Antonio and Soriano, Alex and García, Felipe and SILCOR study group, SILCOR study group},
  title = {Effects of Siltuximab Versus Corticosteroids in Preventing COVID −19 Pneumonia Disease Progression: Multicentre, Open‐Label, Randomized Clinical Trial},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70491}
}
Kostenlos starten →